Aurisco Pharmaceutical (605116.SH) passed the drug Good Manufacturing Practice (GMP) compliance inspection.

Aurisco Pharmaceutical (605116.SH) announced recently that the company has received the "Drug GMP Compliance Inspection Notice" (Zhe 2025 No. 0267, Zhe 2025 No. 0268) issued by the Zhejiang Provincial Drug Administration, which includes the inspection scope and related workshops and production lines: 1. active pharmaceutical ingredient (desonide): workshops 806, 863, production line A3; 2. active pharmaceutical ingredient (betamethasone): workshop 802, production line BETB. The company passed the drug GMP compliance inspection this time, indicating that the company's related production lines meet GMP requirements, which will be beneficial for the company to continue maintaining stable product quality and sustainable production capacity to meet market demand for related drugs. The results of this drug GMP compliance inspection will not have a significant impact on the company's performance.